Division of Gastroenterology and Nutrition, Children's National Medical Center, 111 Michigan Avenue NW, West Wing 2.5, Suite 600, Washington DC 20010, USA.
Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):174-7. doi: 10.1038/nrgastro.2010.7.
A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.
Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.
Anti-TNF-agent induced psoriasiform skin rash.
Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.
一名 17 岁白人男性，患有克罗恩病，正在接受抗肿瘤坏死因子 (TNF) 药物英夫利昔单抗的维持输注，出现了新发的银屑病样皮疹。皮疹对局部或口服皮质类固醇治疗无反应，在英夫利昔单抗输注后以及随后给予第二种抗 TNF 药物阿达木单抗后恶化。
完整的病史和体检，包括皮疹形态的评估以及与抗 TNF 药物给药的时间相关性。
抗 TNF 药物诱导的银屑病样皮疹。
停止抗 TNF 治疗。患者选择口服美沙拉嗪和甲硝唑治疗胃肠道症状。
